Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12879020 
Spicer J, et al. (2003) Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Oncogene 22, 4752-6 12879020
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T211-p - MARK3 (human)
Orthologous residues
MARK3 (human): T211‑p, MARK3 iso3 (human): T211‑p, MARK3 iso6 (human): T211‑p, MARK3 (mouse): T211‑p, MARK3 (rat): T211‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma, lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), COS (fibroblast), HeLa S3 (cervical), MCF-7 (breast cell), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human, mink, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LKB1 (human) increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S215-p - MARK3 (human)
Orthologous residues
MARK3 (human): S215‑p, MARK3 iso3 (human): S215‑p, MARK3 iso6 (human): S215‑p, MARK3 (mouse): S215‑p, MARK3 (rat): S215‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma, lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), COS (fibroblast), HeLa S3 (cervical), MCF-7 (breast cell), Mv1Lu (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human, mink, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LKB1 (human) increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.